Overview
Civetta Therapeutics was founded to advance new medicines through small molecule targeting of propeller domains with the goal of developing important therapeutics for cancers and other diseases. Our vision is to build a portfolio of therapeutics by integrating a broad range of expertise in drugging the propeller domains spanning from biochemistry to biology to medicinal chemistry. These efforts will support the creation of near term therapeutics and longer term value in becoming a leader in this space. Civetta was co-founded by William Sellers, a core institute member of the Broad Institute of MIT and Harvard, a faculty member at Harvard Medical School, and faculty member and senior advisor to the president for experimental therapeutics at the Dana-Farber Cancer Institute and Eric Fischer is an Assistant Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and an Independent Investigator, Dana-Farber Cancer